MRK vs AZN stock comparison
Merck & Co. vs. Astrazeneca · data as of November 13, 2026
Merck & Co. (MRK) has a market value of about $364.3B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months Merck & Co. had revenue of $67.4B and Astrazeneca $62.4B.
Both score 2.8 out of 5 on our five checks.
By area, the stronger company is Astrazeneca on value; Merck & Co. on track record; Astrazeneca on financial health; Merck & Co. on shareholder returns.
Astrazeneca is cheaper on earnings (P/E 26.1 vs. 150.8).
Merck & Co. leads on 8 of the compared lines and Astrazeneca on 15.
Side by side
| MRK | AZN | |
|---|---|---|
| Size and price | ||
| Market cap | $364.3B | $286.0B |
| Share price | $147.76 | $184.45 |
| Score | ||
| Overall score (of 5) | 2.8 | 2.8 |
| Value | 0 | 1 |
| Future growth | 2 | 2 |
| Track record | 5 | 4 |
| Financial health | 2 | 3 |
| Shareholder returns | 5 | 4 |
| Valuation | ||
| P/E (TTM) | 150.8 | 26.1 |
| Forward P/E | 17.6 | 16.5 |
| Price / free cash flow | 24.7 | 46.9 |
| Price / sales | 5.4 | 4.6 |
| EV / EBITDA | 32.5 | 14.7 |
| PEG | 7.10 | 1.20 |
| DCF value vs. price | −31% | −38% |
| Business | ||
| Revenue | $67.4B | $62.4B |
| Net income | $2.5B | $11.0B |
| Free cash flow | $14.7B | $6.1B |
| Net margin | 3.6% | 17.7% |
| Gross margin (5-yr avg.) | 73.4% | 76.8% |
| ROIC (5-yr avg.) | 16.3% | 8.4% |
| Growth | ||
| Revenue growth (1 yr) | 1.3% | 8.6% |
| Revenue growth (5 yrs, per year) | 9.4% | 17.2% |
| EPS growth (5 yrs, per year) | 21.2% | 21.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$44.1B | -$26.0B |
| Dividend yield | 2.30% | 1.74% |
| Shareholder yield | 3.7% | 1.9% |
| Analysts | ||
| Upside to average target | +9% | +13% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRK TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Merck & Co. or Astrazeneca?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Astrazeneca 2.8; the table shows where each one is stronger.
Is Merck & Co. cheaper than Astrazeneca?
On trailing earnings, Astrazeneca trades at a P/E of 26.1 and Merck & Co. at 150.8, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Merck & Co. or Astrazeneca?
Over five years Astrazeneca grew revenue about 17.2% a year and Merck & Co. about 9.4% a year.
Which pays a higher dividend?
Merck & Co. yields 2.30% and Astrazeneca 1.74%.
Full Merck & Co. analysis → Full Astrazeneca analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.